Senti Biosciences, Inc. (SNTI) is a Healthcare stock trading at $0.38 (as of 2026-08-21), with a market capitalization of $11.84M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Senti Biosciences, Inc. develops cell and gene therapies using engineered gene circuits intended to reprogram cells based on biological inputs and responses. Its platform focuses on off-the-shelf CAR-NK cells for oncology, including programs for AML, hepatocellular carcinoma, and colorectal cancer.
Understand Senti Biosciences, Inc.: how it makes money
Senti Biosciences develops off-the-shelf CAR-NK cell therapies engineered with gene circuits to sense inputs, compute decisions, and respond inside tumor environments, and its latest reported revenue is categorized as Revenue From Related Party.
The economic model appears to hinge on whether SENTI-202 can produce durable clinical response signals in its early Phase 1 setting (remission and duration metrics), because the company’s latest reported revenue is 0.0B and it has a very large negative operating margin.
Revenue by segment (latest quarter)
Related Party
$0.0B
Business quality (Weak): High scientific specificity (gene-circuit CAR-NK therapy, SENTI-202 program) but currently limited, early-stage proof points and no reported operating revenue in the latest quarter.
Bull case
SENTI-202 is in Phase 1 with 22 patients: The program is actively enrolling and evaluating dose-level responses in its initial clinical setting.
Reported composite complete remission signal in Cycle 1: Composite Complete Remission Rate for Donor X-Characteristic Derived Patient Doses Cycle 1 is 50 percent, and Number of Patients Achieving Measurable Residual Disease Negative Complete Remission at the First Dose Level Evaluated is 2.
Durability signals for MRD-negative complete remission are reported: Duration of Measurable Residual Disease Negative Complete Remission is 4 months for Patient 1 and 3 months for Patient 2.
Bear case
No reported revenue in the latest quarter: For the 2026-03-31 period, revenue_b is 0.0B and segment revenue is only listed as Revenue From Related Party with a value of 0.0B.
Large negative operating profitability: Operating margin for the 2026-03-31 period is -28850.0 percent, indicating continued substantial operating losses.
Early trial outcomes may be sensitive to small patient counts and specific cohorts: Several KPIs are based on limited counts (for example, 22 patients in Phase 1, 2 patients achieving MRD-negative complete remission at the first evaluated dose level).
Efficacy is reported alongside multiple specific sub-conditions: The KPIs provided reference particular categories such as donor X-characteristics and measurables like MRD negativity, which can limit how broadly the results generalize.